Gundersen Health System Center for Cancer & Blood Disorders offers the same leading-edge care as other major cancer centers across the country. The Center has built a reputation for proven quality, high patient satisfaction, expert specialists, superior technical support, sophisticated treatments and state-of-the-art technology. But don’t just take our word for that.
Gundersen's Center for Cancer & Blood Disorders is among a premier group of hematology-oncology practices in the nation recognized for meeting the highest standards for quality cancer care. This is evidenced through our reaccreditation by the Quality Oncology Practice Initiative (QOPI®) Certification Program, an affiliate of the American Society of Clinical Oncology.
Gundersen first attained QOPI certification in July 2010—and was among the first practices in the nation to be recognized. Our commitment to excellence and quality improvement in cancer care continues.
The American College of Surgeons awarded Gundersen an Outstanding Achievement Award from its Commission on Cancer
(CoC). Gundersen ranks at the high end of an already select group of facilities offering state-of-the-art cancer care.
The CoC sets standards for cancer care facilities, evaluates their resources and quality of care, and studies patterns of patient care and outcomes.
As an Active Institutional Member of the Association of Community Cancer Centers (ACCC), Gundersen supports association efforts to promote the continuum of quality cancer care: research, prevention, screening, early detection, diagnosis, treatment, psycho-social services, rehabilitation and hospice.
Gundersen Radiation Oncology, a proven leader in this discipline, has been accredited since 2002 by the American College of Radiology. ACR accreditation hallmarks quality of care for physicians and patients choosing the right place for radiation therapy, an integral part of state-of-the-art cancer care. Gundersen's radiation therapy team ranks with the best in the country for its approach to care emphasizing quality assurance and quality improvement programs as well as patient satisfaction.
NCI $12.5 million grant will help expand clinical cancer research
The National Cancer Institute (NCI) has awarded a $12.5 million grant to Gundersen Medical Foundation, Marshfield Clinic Research Foundation (MCRF) and St. Vincent Regional Cancer Center in Green Bay to expand their clinical cancer research over the next five years.
The grant, part of NCI’s newly formed National Community Oncology Research Program (NCORP), was announced in conjunction with 52 additional NCORP grants that support cancer research nationwide.
The three healthcare organizations, working as WiNCORP, will build upon their collaborative relationship to improve access to cancer trials for more patients.
The goal of the NCORP network is to bring cancer clinical trials, as well as cancer care delivery research, to individuals in their own communities, generating evidence that contributes to improved patient outcomes and a reduction in cancer disparities.
The network is made up of investigators, cancer care providers, academic institutions and other organizations that provide care to diverse populations in community-based healthcare practices across the United States. The program’s total funding is $93 million a year for five years.
Gundersen, along with MCRF and St. Vincent, worked previously with NCI as part of its Community Clinical Oncology Program (CCOP). Gundersen was also part of NCI’s Community Cancer Centers Program (NCCCP). Both programs preceded NCORP.
Learn more at ncorp.cancer.gov.